current page

Newsroom 2017

January 31, 2017

Terumo Opens a Branch in Yangon
Aiming to Contribute to the Development of Medical Technologies in Myanmar

TOKYO, JAPAN – Jan. 31, 2017 – Terumo Corporation (TSE: 4543) announced today that its Yangon Branch opened for business in January 2017.

In Myanmar, economic growth has been strong1 and healthcare market has been expanding since the country’s transition from military rule to a civilian government in 2011. Growth is projected to continue in the future, but maintenance of healthcare systems and facilities has been falling behind.2

Terumo began doing business in Myanmar in the 1990s,3 and has continuously engaged in commercial activities in the country since that time. As a result, Terumo now has substantial market shares in Myanmar for a wide range of products, including interventional systems, oxygenators, blood bags, blood glucose monitors, and infusion systems. By opening a branch in Yangon, the country’s largest city, Terumo intends to establish more locally based operations and expand its business while also aiming to contribute to the development of medical technologies in the country by offering healthcare training and other initiatives.

Overview of the Yangon Branch

Name:    Terumo Singapore Pte. Ltd. (Yangon Branch)
Location:    Yangon, Myanmar
Date of establishment:    June 23, 2016
Date of opening:    January 9, 2017
Number of employees:    3 (As of January, 2017)

1. Real GDP is forecast to grow between 6 – 9% annually according to the International Monetary Fund’s World Economic Outlook Database

2. According to a report on global healthcare conditions published by Japan’s Ministry of Foreign Affairs

3. Sales are mainly carried out through local sales agents

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

 

Return to page top